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Abstract	  
Gene switches, also known as transcription factors, are important components of genetic 
circuits, and they have wide utility in synthetic biology, gene therapy, and developmental 
biology. Small molecule inducible gene switches are especially valuable as they offer an 
easy way to regulate target genes using an external signal. By combining DNA binding 
domain, ligand binding domain, and activation domain, chimeric gene switches can be 
engineered to turn on or off a user-defined target gene or set of genes, in response to a 
user-defined chemical signal. 
 
In this thesis, we will explore some applications of gene switches in eukaryotic systems. 
First, we report the development of a gene switch that is able to regulate the endogenous 
VEGF-A expression in mammalian cell. The gene switch is specifically and reversibly 
controlled by 4,4’-dyhydroxybenzil, a small molecule, non-steroid synthetic ligand, 
which acts orthogonally in a mammalian system. After optimization of the gene switch 
architecture, a VEGF-A induction ratio of ~200× can be achieved in HEK293 cells at 
micromolar concentrations of DHB.  
 
Second, we report the development of a system to assemble a multi-gene pathway and 
subsequently regulate the entire pathway in yeast using an estradiol gene switch. To 
demonstrate the utility of the system, we assembled the 5-gene zeaxanthin biosynthetic 
pathway in a single step and showed the ligand dependent, coordinated expression of all 
5 genes as well as the tightly-regulated production of zeaxanthin. 
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Chapter	  1:	  Introduction	  
1.1	   Transcription	  factors	  
Over 300 distinct cell types can be found in the human body. They perform a diverse set 
of functions and adopt highly specialized structures, but they all share a single genome. 
This amazing feat is possible only through sophisticated gene regulations (1, 2). Gene 
regulation occurs at many levels, at the first level, epigenetics factors such as DNA and 
histone methylation regulate genes by controlling their accessibility (3, 4). At the second 
level, transcription factors regulate genes by controlling their transcription rates (5, 6). At 
the third level, combinations of mRNA processing and translation machineries regulate 
the production of gene products by controlling mRNA stability and translation rate (7, 8). 
Finally, gene products themselves can be regulated through processes such as allosteric 
interaction and phosphorylation (9, 6). 
 
Situated early in the chain of regulators, transcription factor is the first control point that 
offers both high spatial and temporal resolution. As the gatekeepers of genetic 
information, and they are powerful modulators of everything from life (metabolism (10)), 
growth (developmental patterning (11)), disease (oncogenesis (12)) and death (apoptosis 
(13)). The ability to engineer and control transcription factors is therefore an endeavor of 
fundamental importance and infinite potential. 
 
By definition, transcription factors are protein switches that control the flow of 
information from DNA to mRNA. Functionally, it can be divided into two classes – 
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activators and repressors. As their name implies, activators increase a gene’s transcription 
rate, whereas repressors decrease it. Structurally, most transcription factors are modular 
with at least two modular domains – the DNA binding domain recognizes and binds to a 
specific DNA sequence, and the activation domain recruits the transcriptional 
machineries to initiate transcription (5). Some transcription factors can also contain 
additional domains such as a ligand-binding domain that interacts with chemical signals 
(14). Gene switch is another name for transcription factor, and it makes its cellular 
function more apparent. The two terms are often used interchangeably.  
 
1.2	   Estrogen	  receptor	  alpha	  
The estrogen receptor alpha belongs to the nuclear receptor family of proteins. It is a 
ligand-inducible transcription factor that responds to estrogen and activates the 
transcription of a set of genes. The human estrogen receptor alpha (ERalpha) can be 
divided into 6 separate domains, classically indexed A through F (15, 16). The A/B 
domain is the transcriptional activation domain and is capable of ligand-independent 
activation. The C domain is the DNA-binding domain (DBD), which consists of two 
zinc-fingers recognizing the estrogen response element (ERE) (17). Since ERalpha 
functions as a dimer, the ERE is made up of two palindromic half-sites: AGGTCA NNN 
TGACCT (18). Domain D is a hinge domain that also participates in dimerization, 
nuclear localization, and co-activator binding (19).  Domain E is the ligand-binding 
domain (LBD), consisting of 12 alpha helices that form a hydrophobic ligand-binding 
pocket (20). The natural ligand is 17β-estradiol, but it is also capable of binding to a large 
number of other ligands (21). Some ligands, such as 17β-estradiol, activate ERalpha, and 
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are known as an agonist (20), while others can inactivate ERalpha, among them, the most 
notable antagonistic ligand is tamoxifen, which is used in the treatment of ER positive 
breast cancers (22). Lastly, Domain F is responsible for modulating the activity of 
ERalpha, and is involved in agonist and antagonist distinction (23). 
 
Without ligand binding, the ERalpha remains as a monomer and is bound to Hsp90 (24). 
Ligand binding triggers a conformational change that releases ERalpha from Hsp90, thus 
allowing it to dimerize (25). The dimer can now recognize the ERE and binds to ERE-
containing promoters. The activation domain, together with co-activators such as SRC-1, 
will then recruit the rest of the transcriptional machineries and start transcription (16). 
1.3	   Engineering	  gene	  switches	  
Due to the modular nature of transcription factors, the different domains can be 
exchanged to achieve chimeric function. As a corollary, the different domains can also be 
engineered independently to achieve a totally novel function.  
1.3.1	   DNA-­‐binding	  domains	  
The targeting specificity of a gene switch controls is determined by its DBD. By 
engineering DBDs that can bind specifically to the promoter of interest, the 
corresponding gene can be regulated by the gene switch. Traditionally, the Cys2-His2 
zinc finger DBD is the most frequently engineered DBD, and it is also extremely 
common in naturally occurring mammalian transcription factors (26, 27). Each Cys2-
His2 zinc finger can recognize 3bp of DNA sequence. A collection of zinc fingers that 
recognize any conceivable DNA triplet can theoretically be used to construct zinc finger 
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concatemer that recognize any DNA sequence (28, 29). In reality however, zinc fingers 
have strong preference for guanine, so the functional triplets are therefore mostly guanine 
rich, thus limiting the range of DNA sequences that can be targeted. Furthermore, zinc 
fingers are not entirely modular and inter-finger interaction can make zinc finger 
multimer functionally unpredictable (26, 30). By building a large collection of zinc finger 
monomers and dimers, and combine that with high-throughput screening capability, most 
of the difficulties, except target preference, can be alleviated. Currently, commercial 
custom zinc finger maker (Sigma Aldrich, St Louis, MO) can routinely produce zinc 
finger DBDs with an 18 bp recognition site. 
1.3.2	   Ligand-­‐binding	  domain	  
The ligand-binding domain (LBD) determines the chemical signal to which an inducible 
gene switch responds. However, most natural occurring LBD, as intended by nature, 
responds to endogenous ligands. When employed in its native host, the LBD will 
experience interference from the host’s ligands. For instance, if ERalpha LBD is used in a 
gene switch for a mammalian system, endogenous estrogen may activate the gene switch 
independent of external control. Furthermore, when exogenous estrogen is used to control 
the gene switch, it will inadvertently wreak havoc with the host’s endocrine system (21). 
It is therefore important to have orthogonal ligand-receptor pairs, so that the gene switch 
and its corresponding ligand can act orthogonally to the host’s system.  
 
Two approaches can be taken to achieve orthogonality. In one approach, we can use a 
LBD from a heterologous origin that has no homolog in its intended host. For example, 
human ERalpha can be used orthogonally in yeast, and bacterial tetracycline repressor 
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can be used orthogonally in human (31, 32). In the other approach, the LBD can be 
engineered to respond to new synthetic ligands to form novel orthogonal ligand-receptor 
pairs. 
1.3.3	   Activation	  domain	  
The activation domain determines how the gene switch interacts with the transcriptional 
machineries. The structural requirement for an activation domain is rather 
undiscriminating: (1) they often have an abundance of acidic residues, and (2) an alpha 
helix appears necessary (5). Given the lack of stringent criteria, activation domains are 
unsurprisingly promiscuous, i.e. if an activation domain works in one eukaryotic cell, it 
will likely work in many eukaryotic cells from any species (5). Two of the most 
commonly used eukaryotic activation domains are VP16 and VP64, both derived from 
the human herpesvirus (33). The activation domain can also be replaced by other 
functional domains such as a repression domain, which will create a ligand-inducible 
repressor instead of an activator (33).  
1.3.4	   Previous	  studies	  in	  Zhao	  group	  
The seminal works of previous lab members laid the foundation for my thesis. First, 
Karuppiah et al. established a method to switch the ligand specificity of ERalpha. Based 
on the crystal structure of the ER LBD, 20 sites lining the ligand-binding pocket were 
chosen for saturation mutagenesis. After initial rounds of iterative saturation mutagenesis, 
the positive mutant was then subjected to random mutagenesis to further its specificity 
and sensitivity. Through this method, he showed that novel orthogonal ligand-receptor 
pairs can be systematically developed (34). Second, McLachlan et al. introduced the 
synthetic gene switch architecture, where an engineered zinc finger DBD, an engineered 
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LBD, and a general acidic activation domain were fused to create an artificial 
transcription factor (35). He also demonstrated the use of orthogonal gene switches in 
gene circuit construction using ligand-inducible activators and repressors (36).  
1.4	   Applications	  of	  gene	  switches	  
In this thesis, I will address the continued development of the gene switch architecture for 
endogenous gene regulation and exogenous gene regulation. 
1.4.1	   Endogenous	  gene	  regulation	  
The ability to control endogenous genes has applications in gene therapy and biological 
research. In cases where a disease state is caused not by the total lack of a gene, but 
rather, by the uncoordinated or unsynchronized production of a gene product, regaining 
control over the endogenous gene locus could be an equally if not more effective solution 
than simply inserting another copy of the gene. Controlling the expression of endogenous 
genes can also be a valuable tool for interrogating fundamental biological questions. The 
high temporal control of gene switches allows researchers to turn on or off a gene of 
interest at a desired time point so that its effect can be studied.  
 
Chapter 2 describes the ligand-inducible activation of endogenous vascular endothelial 
growth factor A (VEGF-A) in a human cell line. VEGF-A is an important signaling 
molecule in angiogenesis, and it plays a significant role in growth, recovery as well as 
disease. Using an engineered LBD and optimized single-chain gene switch architecture, 
endogenous VEGF-A can be induced, by an orthogonal synthetic chemical ligand, up to 
250-folds, which is among the best endogenous gene activation reported in literature. We 
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further demonstrate that VEGF-A expression can be tightly and reversibly controlled, 
thus enabling an easily customizable dosage profile that is important for proper 
angiogenesis. This gene switch architecture can serve as the template for developing 
future gene switches to target any endogenous gene. 
1.4.2	   Exogenous	  gene	  regulation	  
When exogenous genes are introduced into a host, indiscriminate overexpression will 
often lead to counter productivity. The logic is obvious when the gene products or the 
biosynthetic pathway products are toxic to the host, but it is also true for non-toxic 
products.  If the product interacts with the host’s genetic network, indiscriminate 
overproduction will lead to imbalance and poor overall fitness. Even when there is no 
direct interaction, channeling energy and metabolites aimlessly to overproduction is a 
futile exercise for the host. It is therefore often desirable to put any introduced genes 
under the control of an inducible production system. 
 
Chapter 3 describes the development of a coordinated induction system for expressing 
heterologous multi-gene pathways in yeast. Using an ERalpha based gene switch in 
combination with a set of auxiliary strains and plasmids, multi-gene pathways can be 
easily assembled, and the resultant pathways are inducible by estrogen. As oppose to 
galactose, estrogen can be used in the presence of glucose, thus enabling the direct 
addition of estrogen to a culture without media change. Due to the exceptional sensitivity 
of ERalpha, only a minute quantity of estrogen is required to fully activate a large 
culture, making this a highly cost-effective method for industrial scale induction.  
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1.6	   Figures	  
Figure 1.1 Estrogen receptor alpha domains. Amino acid position, domain index and 
function indicated. 
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Chapter	  2:	  Orthogonal	  control	  of	  endogenous	  gene	  expression	  in	  
mammalian	  cells	  using	  synthetic	  ligands	  
2.1	   Introduction	  
Since their inception, small-molecule controlled transcription regulators, or gene 
switches, have been powerful tools in many areas of biological and biomedical sciences.  
For example, in developmental biology, signaling pathways can be dissected through 
temporal suppression and expression of genes within the pathways.  In gene therapy, the 
induction of a beneficial gene product can be regulated to fall within a therapeutic 
window or ceased when necessary (1-4).  With the advent of synthetic biology, complex 
gene circuitries can be built from a set of well-behaved gene switches, thus creating 
further demand for orthogonal gene switches (5, 6).  In addition, there is a growing 
interest in controlling complex phenotypes, especially in mammalian cells.  Controlling 
complex phenotypes requires the remodeling of an intricately interconnected genetic 
network.  Due to the network’s size and complexity, many cellular phenotypes are 
inaccessible via the control of a single gene locus.  For example, the induction of 
pluripotency in human somatic cells requires the simultaneous induction of at least three 
genes (7-9).  To maximize the control over the genetic network, it is highly desirable not 
only to control multiple genes at the same time, but also to control them using 
independent orthogonal ligands.  
 
The aim of this work is to develop a framework for the engineering of orthogonal 
mammalian gene switches, and demonstrate its utility through the ligand-dependent 
induction of an endogenous gene. Compared to typical multi-copy plasmids, genes on the 
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chromosome has a much lower copy number, and the induction of endogenous loci is 
often more challenging, therefore placing higher requirement on the efficiency of the 
design.  Induction of endogenous genes is of particular interest in mammalian systems 
because its gene products have shown better therapeutic efficacy compared to those of an 
exogenous gene, possibly by providing the necessary splice variants (10).  Such 
functionality will also be useful to developmental biology and synthetic biology because 
it sometimes takes multiple splice variants working in tandem to achieve a desired 
biological effect (10).  
 
Tetracycline receptor, ecdysone receptor, chemical dimerizers, and nuclear hormone 
receptor are among the leading platforms for mammalian gene regulation (4).  In this 
study, we focus on the nuclear hormone receptor platform because (a) the protein can be 
fully humanized, which minimizes the chance of immune response, (b) the ligand 
specificity can be engineered and changed to create orthogonal ligand-receptor pairs, and 
(c) its modular design allows convenient change of its DNA binding domain to target 
different genes.  Under the nuclear hormone receptor platform, the ligand-binding 
domain from a nuclear hormone receptor, e.g. estrogen receptor and progesterone 
receptor, is fused with a zinc-finger DNA binding domain that binds to the promoter 
region of the target gene.  Although estrogen receptor itself has slight activation ability, 
an activation domain, e.g. VP16, VP64, or p65, is typically added to enhance its 
induction power (11). 
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The ligand-induced regulation of endogenous genes has been previously demonstrated 
using such a gene switch platform (12, 13).  However, two main shortcomings currently 
limit the utility of this platform.  First, the ligands used for induction are not orthogonal 
to natural occurring nuclear hormone receptors, and have potent biological effect in 
mammalian systems.  Second, the basal expression from the platform is considered 
somewhat leaky compared to the tightly controlled tetracycline receptor platform.  This 
can be due to the natural occurrence of hormones in the mammalian system or the 
presence of an ectopic overexpression of an activation domain.  In a recent study, 
Schwimmer et al. have partially addressed the first problem through the development of a 
benzoate X receptor gene switch (14).  However, this has yet to be demonstrated in an 
endogenous context. 
 
In this study, we aim to address these main limitations.  To create orthogonality, we 
utilized a previously engineered estrogen receptor ligand binding domain (LBD) that is 
sensitive to 4,4-dihydroxybenzil (DHB) – a synthetic non-steroid ligand that acts 
orthogonally to estrogen (Figure 2.1) (15, 16). The LBD consists of amino acids 312-595 
of the human estrogen receptor alpha, and the engineered version, called 4S LBD, has 
mutation A350M, L346I, M388Q, G521S, Y526D. DHB is synthetic ligand that is 
structurally similar to diethylstilbestrol, a FDA approved drug, and it has been shown to 
have low cytotoxicity in cell culture and low systemic toxicity in mouse model (15, 17).  
 
The vascular endothelial growth factor A (VEGF-A) was chosen as a model target for 
this study.  VEGF-A is an important signaling molecule in angiogenesis, and its 
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regulation has many therapeutic applications (18).  For example, the up-regulation of 
VEGF-A can help new blood vessels formation as a treatment for ischemia, whereas the 
down-regulation of VEGF-A can restrict the growth of tumors (19, 20).  To target the 
endogenous VEGF-A loci, we have utilized VZ-8, a zinc-finger DNA binding domain 
(DBD) engineered by Liu et al., which recognizes a 9 base pairs site within the VEGF-A 
promoter, and has been shown to activate VEGF-A expression when combined with an 
activation domain (21).  
 
In this work, we have combined the VZ-8 DBD, the 4S LBD, and the p65 activation 
domain to make our gene switch. The human p65 protein is part of the NF-κB activation 
complex (22).  It is 551 amino acids (aa) long and most of the activation activity is 
localized at the C-terminal region (23). To minimize basal expression level and maximize 
induction level, we performed domain length optimization of the p65 activation domain, 
as well as domain permutation and linker optimization of the overall architecture.  
 
When transiently transformed into HEK293 cells, our construct in the absence of DHB 
showed no VEGF-A expression beyond the normal basal level.  When induced with 1 
µM DHB, a 170-fold increase in VEGF-A expression was observed.  This induction was 
roughly twice as high as that achieved with a constitutive construct.  When stably 
integrated into HEK293, >250-fold induction was observed with no detectable basal 
expression.  This gene switch has among the highest performance characteristics as 
compared to previously reported endogenous gene induction studies.  Furthermore, it 
provides the architecture to combine the zinc-finger DBD technology with the ligand 
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specificity engineering technology, and brings us one step closer to the ability to control 
multiple genes with multiple orthogonal ligands. 
2.2	   Results	  
2.2.1	   Domain	  permutations	  
We attempted to use our gene switch to induce the endogenous VEGF-A expression in 
HEK293 cell line.  HEK293 was chosen in the induction study because of its low basal 
VEGF-A level, and its widely reported use in endogenous VEGF-A induction studies (21, 
13, 24).  Our initial construct, p65-VZ8-4S, did not show any induction activity.  We 
proceeded to try a set of different domain permutations as listed in Figure 2.2.  The last 
two dual LBD single-chain constructs, V24P and P24V, were by far the best performing 
constructs, outperforming the rest by at least 5 fold (Figure 2.3). 
2.2.2	   Single-­‐chain	  gene	  switch	  optimization	  
The estrogen receptor LBD dimerizes during the process of ligand activation, and it has 
been shown that a single-chain estrogen receptor – comprised of two LBDs fused 
together – can activate gene expression by intramolecular dimerization (25, 12).  Since it 
was unclear how two chimeric estrogen receptor gene switches would dimerize, we 
postulated that the linker length between the LBDs could affect dimerization and thus its 
activation characteristics.  A set of single-chain gene switches from the V24P and P24V 
constructs was constructed by inserting between the two 4S LBDs varying lengths of GS 
linkers (G4S)n ranging from 20 to 110 aa long (Figure 2.2).  This set of gene switches was 
transiently expressed in HEK293 cells under the CMV promoter, and the VEGF-A 
concentration was assayed by ELISA 24 hours after DHB induction.  
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As shown in Figure 2.4A, it was found that in the V24P construct, induction level peaked 
with a 60 aa linker, which offered a 20% improvement over the construct with no linker.  
Furthermore, the basal expression level decreased with increasing linker length, 
bottoming out also at 60 aa.  The induction ratio for V24P-GS60 was about 170-fold.  A 
peak induction level of 2456 pg/mL was achieved, which was significantly higher than 
even the constitutive constructs VZ8-P65 and F435P.  The basal level was around 13 
pg/mL, lower than the EGFP negative control, but higher than the Gal-P65 negative 
control.  VZ8-P65 consists of a VZ8 DBD fused directly to a p65 activation domain, and 
served as constitutive activator of VEGF-A, whereas F435P is another zinc-finger based 
constitutive activator of VEGF-A obtained from Bae et al. (26), and served as a 
benchmark for the observed induction level.  Gal-P65 consists of a Gal4 DBD fused 
directly to a p65 activation domain, and served as a control for any non-specific induction 
caused by ectopic expression of p65. 
 
The P24V construct offered a different profile of activation.  While the induction level 
appeared independent of linker length, the basal expression level increased with 
increasing linker length.  The strength of induction of the P24V construct was less than 
half that of V24P, but the basal level for P24V was only 3 pg/mL (outside of standard 
curve), which was comparable to the Gal-P65 negative control.  The very low basal 
expression gave the P24V construct an induction ratio of 300-fold despite its lower peak 
induction level.  
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2.2.3	   Time	  response	  
The speed of activation is an important gene switch parameter.  Being a constitutively 
expressed single-step transcriptional switch, it is expected to be slower than translational 
switches, but comparable to that of a Tet-On system controlling a transgene (27).  To 
characterize the response time of the gene switch, we added DHB to identical wells at 
one-hour intervals, and assayed their VEGF-A concentration at the end of 12 hours 
(Figure 2.4B).  VEGF-A production was clearly detectable from 3 hours onwards, and 
increased steadily thereafter. 
2.2.4	   Ligand	  response	  
V24P-GS60 was chosen for further characterization because of its high induction power, 
and we hypothesized that the basal level could be reduced with lower gene switch 
expression level.  For further characterization, the P24V-GS60 gene switch was 
integrated into the chromosome of HEK293 via retroviral integration and antibiotic 
selection.  At first, single-clone isolation was not carried out because we wanted to see 
how the integrated switch behaved in aggregate, given that individual clones vary in their 
performances.  
 
Compared to the plasmid version, the integrated version was slightly less sensitive to the 
ligand, possibly due to a lower gene switch expression level from the reduced copy 
number per cell.  An induction level of 1895 pg/mL was achieved at 1 µM DHB and 
2519 pg/mL was achieved at 10 µM DHB, giving an induction ratio of ~250-fold (Figure 
2.5A).  The induction appeared to taper off at 10 µM, but cell numbers were significantly 
less at high inducer concentration.  Therefore, the cell number was counted at the time of 
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sample collection and normalized by the measured VEGF-A level.  It was found that, 
after normalization to cell number, there was no attenuation of induction up to 10 µM 
DHB.  However, increasing the ligand concentration beyond 10 µM was impractical due 
to severe impairment on cell growth.  The growth impairment most likely came from the 
heavy metabolic burden under high induction, because no effect on cell growth could be 
observed in cells not expressing the gene switch, even after prolonged DHB and/or 
VEGF-A exposure. The induction was log-linear to ligand concentration over at least 2 
orders of magnitude.  This characteristic allowed the switch to be tuned by external 
ligand concentration and achieve induction of different strengths.  
 
Despite its usefulness in fine-tuning gene expression, a gently sloped ligand titration 
curve was atypical for a 4S LBD gene switch (15).  Suspecting that this observation 
might be an aggregated behavior, 12 clonal cell lines were isolated from the 
heterogeneous population, and tested for their VEGF induction level at 1 µM DHB.  The 
induction level ranged widely from 810 to 5100 pg/mL, and the average of the 12 clonal 
cell line was 2740 pg/mL, which was close to that obtained from the whole 
heterogeneous population (Figure 2.6).  When we picked the most inducible clone and 
performed a ligand titration, we obtained a nearly perfect sigmoidal response with a 
Hill’s coefficient of 2.3, and a Km of 38 nM (Figure 2.5B).  Further tests on other clones 
reflected that the Km varies between clones (Figure 2.5C).  
 
We propose that the ligand titration curve of the heterogeneous population is a weighted 
sum of a series of perfectly sigmoidal curves with different Km.  As seen in Figure 2.5D, 
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using just 8 evenly spaced sigmoidal curves as the basis set, we can fit the observed 
heterogeneous ligand titration curve very well by assigning different weightage to them. 
2.2.5	   Sustained	  induction	  and	  reversal	  
In some applications, long-term sustained induction might be required, whereas in other 
applications, short intervals of repeated induction might be preferable.  To characterize 
the long-term induction, induction reversal, and repeated induction behavior of the gene 
switch, the stably integrated HEK293 cells was subjected to three 16-day time courses 
(Figure 2.7).  The first set of experiments was performed using the heterogeneous 
population of integrants.  In time course 1, the cells were induced for 2 days followed by 
6 days of rest; in time course 2, the cells were induced for 4 days followed by 4 days of 
rest; and in time course 3, the cells were maintained at 1 µM DHB through the entire 
duration.  All values were normalized to the cell number at the time of sampling. 
 
In time course 1 (Figure 2.7A), the VEGF-A production level increased quickly to about 
2700 (pg/mL/24h) one day after ligand addition, and increased further to 3700 
(pg/mL/24h) on the second day.  The VEGF production decreased quickly upon ligand 
withdrawal, reaching basal level in two days.  When the cells were re-induced on day 9, a 
similar behavior was observed.  This showed that the induction was reversible and 
repeatable.  In time course 2 (Figure 2.7B), the daily VEGF-A production level increased 
initially for 3 days, reaching up to 4800 (pg/mL/24h).  However, VEGF-A production 
dropped on the 4th day despite continued induction.  The induction sensitivity was only 
partially recovered after 4 days of rest, and a drop in induction level was still observable 
on the 4th day of re-induction.  During sustained induction in time course 3 (Figure 2.7C), 
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a similar trend was observed for the initial 3 days of induction.  The induction level then 
decreased steadily from the 4th day onwards.  After 15 consecutive days of induction, the 
VEGF-A production level dropped to near basal level.  
 
It was found that sustained induction could only be maintained using a clonal integrant 
cell line, and at such a level that it does not affect cell growth.  The sustained induction 
time course was repeated using a highly sensitive clone at 20 nM DHB, which 
corresponds to an induction level of about 1000 (pg/mL/24h).  At this level, the induction 
can be sustained for the entire duration of the time course (Figure 2.7D).  To demonstrate 
that the cells were still capable of high induction, the maximum induction of 5500 
(pg/mL/24h) was elicited using 200 nM DHB on day 1 and again on day 9.  
2.2.6	   Localization	  
Because of the low VEGF-A background in our test cell line, we were unable to 
determine if the presence of the un-induced gene switch had any effect on the VEGF-A 
expression.  It was plausible that the DNA binding domain could still bind to the 
promoter and affect native transcription.  To test this possibility, a localization study of 
the gene switch was performed, i.e. if the gene switch were mostly cytosolic when un-
induced, then the likelihood of it affecting native transcription would be low. 
 
The EGFP gene was fused to the N-terminus of our gene switch and confocal microscopy 
was used to visualize where the gene switches were localized in the cell (Figure 2.8).  To 
ensure the EGFP-fused gene switch would behave similarly, its induction activity was 
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also assayed.  The activity data showed that the EGFP fusion protein was active, albeit at 
a lower level most likely due to a reduced expression level. 
 
The confocal images indicated that the gene switch was mostly localized within the 
nucleus with and without ligand.  The natural estrogen receptor is known to reside mostly 
in the nucleus and the presence of an engineered ER LBD alone appears sufficient to 
confer this localization property.  For natural full length ER, the un-induced receptor is 
bound to heat shock protein (hsp90), which prevents dimerization and blocks the 
transcription regulation activity of the receptor.  In contrast, it has been reported that the 
ER LBD alone is insufficient for binding to hsp90 (28).  Whether this is true for our 
engineered gene switch remains to be tested.  
 
2.3	   Discussion	  
In this chapter, we have demonstrated that our gene switch is able to induce endogenous 
VEGF expression in HEK293 cells using a non-steroid orthogonal ligand.  An induction 
ratio of over 100-fold can be achieved at µM ligand concentration.  We have also shown 
that the induction is fast, reversible, and sustainable as long as the cellular machinery can 
support it.  
 
To highlight the performance of our gene switch, it is important to make some cross 
comparisons with the performance of previously reported gene switches.  This is, 
however, difficult due to differing assay conditions.  We have summarized previously 
reported VEGF induction values, be it inducible or constitutive, and made reasonable 
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comparisons whenever possible (Table 2.1).  Overall, our gene switch assay has among 
the lowest initial cell number and among the shortest accumulation time, and yet, has the 
highest peak VEGF induction value.  Pollock et al. normalized their VEGF assay by total 
cellular protein content, and is therefore not directly comparable (29).  Fortunately, both 
Pollock et al. and Liu et al. have included hypoxia positive control which suggests that 
Pollock’s assay conditions yield values roughly 8.5 times that of Liu’s (29, 21).  Liu’s 
and Dent’s studies share a common construct, VZ+434-P65, and their relative value 
suggests that Dent’s assay yields values roughly 3.5 times that of Liu’s (21, 13).  Our 
study shares a common construct with Bae et al., F435P, which suggests that Bae’s assay 
yields value roughly twice ours (26). 
 
Taken together, our gene switch produces the highest peak induction value as well as the 
highest induction ratio, even when compared with constitutive constructs.  It should be 
noted that induction ratio is highly dependent on basal level expression, and due to the 
low basal level expression under non-induction condition, our low-end measurement 
values are often too close to the detection limit of the ELISA assay to be dependable.  
This is especially true in the case of an integrated gene switch in a heterogeneous 
population, where the measured VEGF-A value is effectively zero.  In that case, we have 
used the ELISA detection limit (around 10 pg/mL) to calculate the induction ratio.  We 
have excluded from comparison the clonal assays value, which has a peak of 4588 
pg/mL, because it varies between cell lines and we do not believe that it is a good 
representation of the gene switch’s performance. 
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In the presence of the uninduced gene switch, the basal VEGF-A level appears lower than 
the negative control.  This is the most pronounced in the integrated HEK293 cell line.  
Since our localization study found that the gene switch resides mostly in the nucleus with 
and without induction, it is possible for the DBD to bind and disrupt regular transcription.  
However, due to the high uncertainty associated with low value measurements, we are 
unable to determine if the un-induced gene switch represses VEGF-A transcription. 
 
We have shown that the induction is reversible and repeatable.  However, we are unable 
to sustain the induction over a long period of time in a heterogeneous population.  This is 
because cell growth is inhibited and cell death is triggered at a high induction level, most 
likely due to overwhelming metabolic burden.  Since the heterogeneous population 
contains cell lines that have a wide range of ligand sensitivity, we are effectively 
enriching the non-secreting and low-secreting cells by killing off the highly inducible 
ones.  In a clonal cell line, induction is sustainable at a level that does not affect cell 
growth.  Unfortunately, this is achieved at a ligand concentration that is around the Km, 
where the induction level is most sensitive to minute differences in ligand concentration, 
thus leading to large errors of measurement. 
 
We also see important differences in the behavior of the heterogeneous and the clonal 
integrant populations.  For example, the ligand response curve is much gentler in a 
heterogeneous population which allows for finer control of induction level.  
Theoretically, by mixing a finite set of clonal population of different ligand sensitivities, 
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we can tune the ligand response curve of the mixed population to achieve a sensitivity we 
desire.  
 
As a ligand, DHB has shown very little toxicity in multiple cell lines, with IC50 greater 
than 100µM.(30) Similarly, DHB has also been found to have low systemic toxicity in 
mice, and intraperitoneal (IP) injection of 1 mg/kg is well tolerated. While DHB is stable 
in cell culture media for days, it is either rapidly cleared from or modified in mice with 
no detectable DHB remaining in blood 24h after IP injection. Despite the apparent short 
half-life, DHB has been successfully used to trigger recombination in mice through a 
Cre-ER fusion protein. The recombination efficiency observed using the DHB-4S ligand-
receptor pair was comparable to that of the tamoxifen-ERT pair (31, 17). 
2.4	   Conclusions	  and	  Outlook	  
To conclude, we have reported the design and construction of a highly effective ligand-
responsive artificial transcription factor whose performance tops previously reported 
designs.  This study represents the missing link between gene targeting technology and 
ligand specificity engineering, thus making it possible to create multiple orthogonal gene 
switches under the control of multiple orthogonal ligands.  This technology can be 
immediately useful to developmental biologists, and with further development, be useful 
in gene therapy and synthetic biology applications. 
 
The ultimate aim of the technology developed in this study is to create a platform for the 
engineering of orthogonal gene switches that can independently control multiple genes in 
mammalian systems.  The LBD used in our study is responsive to DHB and more 
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orthogonal LBD-ligand pairs can be created through the established method published 
earlier.  In fact, the method has already been successfully applied in multiple studies, 
giving rise to multiple orthogonal LBD-ligand pairs (15, 16, 32).  In order to control 
multiple genes, multiple DBDs also need to be engineered.  Fortunately, zinc-finger DBD 
technology is well established and is now even commercially available (33, 26, 34, 35).  
Looking further, TAL effector DBD is a new class of DBD that promises even better 
modularity than zinc-finger DBD (36, 37).  However, its incorporation into the gene 
switch construct will likely involve redesign and optimization. 
 
2.5	   Material	  and	  Methods	  
2.5.1	   Construction	  of	  gene	  switch	  
The P65 gene segment was PCR amplified and cloned from human cDNA and the 
different truncations were subsequently generated by PCR.  The engineering of the 4S 
ligand-binding domain was described elsewhere (15).  The VZ8 DNA binding domain 
was constructed by overlap extension of DNA oligos as described elsewhere (21).  The 
long GS linker was constructed by overlap extension PCR and the truncations 
subsequently generated by PCR.  The different parts were assembled using unique 
restriction sites introduced in the PCR primers, and cloned into pCMV5 for transient 
expression and into pLNCX2 for stable integration.  A list of plasmids used in this work 
can be found in Table 2.2. 
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2.5.2	   ELISA	  assay	  
HEK293 cell line was obtained from Professor Jie Chen of University of Illinois and 
propagated in DMEM (UIUC Cell Media Facility) with 10% FBS at 37ºC 5% CO2.  48 
hours before sampling, 8x105 cells were seeded into each well of a 24-well plate 
(PureCoat Amine, BD Biosciences).  36 hours before sampling, cells for transient 
expression were transfected by FuGene HD (Promega, Madison WI) according to the 
manufacturer’s recommendation using 500 ng of the appropriate gene switch plasmids.  
30 hours before sampling, ligands were added to appropriate wells.  24 hours before 
sampling, media was changed, and ligands re-added.  After 24 hours of accumulation, the 
supernatant was collected and assayed in duplicate by ELISA.  ELISA kit was obtained 
from R&D Systems (Minneapolis, MN), and performed according to the manufacturer’s 
recommendation. 
2.5.3	   Retroviral	  integration	  
Retroviral integration was performed using retrovirus packaging system from Clontech 
(Mountain View, CA) according to manufacturer’s recommendation.  Briefly, selected 
gene switches were cloned into pLNCX2 retroviral vector.  The retroviral vectors were 
co-transformed together with pVSV-G envelope vector into the GP2-293 packaging cell 
line to produce retrovirus.  Supernatant containing retrovirus was collected after 2 days 
and used to infect HEK293 cells.  One day after infection, HEK293 cells were put under 
1000 µg/mL G418 selection.  The resistant cells were gathered after 2 weeks of selection 
and subsequently used for characterization studies. 
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2.5.4	   Curve	  fitting	  
Curve fitting was performed using OriginPro 8.6.  The clonal ligand titration curve was 
fitted to the Hill equation, ! = !"# + !"# −!"# ∗ !!!!!!!  where n is the Hill 
coefficient and k is the Km.  The heterogeneous population ligand titration curve was 
fitted using a weighted sum of 8 Hill equations. ! = !!!! [!! ∗ ! !"#,!"#,!, !! ]! , 
where f is a Hill equation with min = 0, max = 5000, n = 2.3, ki = [3.3x10-8, 1x10-7, 
3.3x10-7, 1x10-6, 3.3x10-6, 1x10-5, 3.3x10-5, 1x10-4], and a is the weight parameter for 
fitting. 
 
 	  
 29 
2.6	  	   References	  
1. Zhu,Z., Zheng,T., Lee,C.G., Homer,R.J. and Elias,J.A. (2002) Tetracycline-controlled 
transcriptional regulation systems: advances and application in transgenic animal 
modeling. Semin. Cell Dev. Biol., 13, 121–128. 
2. Buskirk,A.R. and Liu,D.R. (2005) Creating small-molecule-dependent switches to 
modulate biological functions. Chem. Biol., 12, 151–161. 
3. Markoulaki,S., Hanna,J., Beard,C., Carey,B.W., Cheng,A.W., Lengner,C.J., 
Dausman,J.A., Fu,D., Gao,Q., Wu,S., et al. (2009) Transgenic mice with defined 
combinations of drug-inducible reprogramming factors. Nat. Biotechnol., 27, 169–
171. 
4. Clackson,T. (2000) Regulated gene expression systems. Gene Ther., 7, 120–125. 
5. Fussenegger,M. (2001) The impact of mammalian gene regulation concepts on 
functional genomic research, metabolic engineering, and advanced gene therapies. 
Biotechnol. Prog., 17, 1–51. 
6. Weber,W. and Fussenegger,M. (2009) Engineering of synthetic mammalian gene 
networks. Chem. Biol., 16, 287–297. 
7. Takahashi,K., Tanabe,K., Ohnuki,M., Narita,M., Ichisaka,T., Tomoda,K. and 
Yamanaka,S. (2007) Induction of pluripotent stem cells from adult human fibroblasts 
by defined factors. Cell, 131, 861–872. 
8. Yu,J., Vodyanik,M.A., Smuga-Otto,K., Antosiewicz-Bourget,J., Frane,J.L., Tian,S., 
Nie,J., Jonsdottir,G.A., Ruotti,V., Stewart,R., et al. (2007) Induced Pluripotent Stem 
Cell Lines Derived from Human Somatic Cells. Science, 318, 1917–1920. 
9. Nakagawa,M., Koyanagi,M., Tanabe,K., Takahashi,K., Ichisaka,T., Aoi,T., Okita,K., 
Mochiduki,Y., Takizawa,N. and Yamanaka,S. (2008) Generation of induced 
pluripotent stem cells without Myc from mouse and human fibroblasts. Nat. 
Biotechnol., 26, 101–106. 
10. Rebar,E.J., Huang,Y., Hickey,R., Nath,A.K., Meoli,D., Nath,S., Chen,B., Xu,L., 
Liang,Y., Jamieson,A.C., et al. (2002) Induction of angiogenesis in a mouse model 
using engineered transcription factors. Nat. Med., 8, 1427–1432. 
11. Elliston,J.F., Tsai,S.Y., O'Malley,B.W. and Tsai,M.J. (1990) Superactive estrogen 
receptors. Potent activators of gene expression. J. Biol. Chem., 265, 11517–11521. 
12. Magnenat,L., Schwimmer,L.J. and Barbas,C.F. (2008) Drug-inducible and 
simultaneous regulation of endogenous genes by single-chain nuclear receptor-based 
zinc-finger transcription factor gene switches. Gene Ther., 15, 1223–1232. 
13. Dent,C.L., Lau,G., Drake,E.A., Yoon,A., Case,C.C. and Gregory,P.D. (2007) 
 30 
Regulation of endogenous gene expression using small molecule-controlled 
engineered zinc-finger protein transcription factors. Gene Ther., 14, 1362–1369. 
14. Schwimmer,L.J., Gonzalez,B. and Barbas,C.F. (2012) Benzoate X receptor zinc-
finger gene switches for drug-inducible regulation of transcription. Gene Ther., 19, 
458–462. 
15. Chockalingam,K., Chen,Z., Katzenellenbogen,J.A. and Zhao,H. (2005) Directed 
evolution of specific receptor-ligand pairs for use in the creation of gene switches. 
Proc. Natl. Acad. Sci. U.S.A., 102, 5691–5696. 
16. McLachlan,M.J., Chockalingam,K., Lai,K.C. and Zhao,H. (2009) Directed evolution 
of orthogonal ligand specificity in a single scaffold. Angew. Chem. Int. Ed., 48, 
7783–7786. 
17. Metzger,D., Chambon,P., Zhao,H. and Katzenellenbogen,J.A. (2010) Method for 
temporally controlling the biological activity of proteins in vertibrates, and 
applications thereof. 
18. Yancopoulos,G.D., Davis,S., Gale,N.W., Rudge,J.S., Wiegand,S.J. and Holash,J. 
(2000) Vascular-specific growth factors and blood vessel formation. Nature, 407, 
242–248. 
19. Bao,P., Kodra,A., Tomic-Canic,M., Golinko,M.S., Ehrlich,H.P. and Brem,H. (2009) 
The role of vascular endothelial growth factor in wound healing. J. Surg. Res., 153, 
347–358. 
20. Ferrara,N. (2005) VEGF as a therapeutic target in cancer. Oncology, 69 Suppl 3, 11–
16. 
21. Liu,P.Q., Rebar,E.J., Zhang,L., Liu,Q., Jamieson,A.C., Liang,Y., Qi,H., Li,P.X., 
Chen,B., Mendel,M.C., et al. (2001) Regulation of an endogenous locus using a panel 
of designed zinc finger proteins targeted to accessible chromatin regions. Activation 
of vascular endothelial growth factor A. J. Biol. Chem., 276, 11323–11334. 
22. Schmitz,M.L. and Baeuerle,P.A. (1991) The p65 subunit is responsible for the strong 
transcription activating potential of NF-kappa B. EMBO J., 10, 3805–3817. 
23. Ballard,D.W., Dixon,E.P., Peffer,N.J., Bogerd,H., Doerre,S., Stein,B. and 
Greene,W.C. (1992) The 65-kDa subunit of human NF-kappa B functions as a potent 
transcriptional activator and a target for v-Rel-mediated repression. Proc. Natl. Acad. 
Sci. U.S.A., 89, 1875–1879. 
24. Tachikawa,K., Schröder,O., Frey,G., Briggs,S.P. and Sera,T. (2004) Regulation of the 
endogenous VEGF-A gene by exogenous designed regulatory proteins. Proc. Natl. 
Acad. Sci. U.S.A., 101, 15225–15230. 
25. Beerli,R.R., Schopfer,U., Dreier,B. and Barbas,C.F. (2000) Chemically regulated zinc 
 31 
finger transcription factors. J. Biol. Chem., 275, 32617–32627. 
26. Bae,K.-H., Kwon,Y.D., Shin,H.-C., Hwang,M.-S., Ryu,E.-H., Park,K.-S., Yang,H.-Y., 
Lee,D.-K., Lee,Y., Park,J., et al. (2003) Human zinc fingers as building blocks in the 
construction of artificial transcription factors. Nat. Biotechnol., 21, 275–280. 
27. Weber,W. and Fussenegger,M. (2007) Novel gene switches. Handb Exp Pharmacol, 
178, 73–105. 
28. Pratt,W.B. and Toft,D.O. (1997) Steroid receptor interactions with heat shock protein 
and immunophilin chaperones. Endocr. Rev., 18, 306–360. 
29. Pollock,R., Giel,M., Linher,K. and Clackson,T. (2002) Regulation of endogenous 
gene expression with a small-molecule dimerizer. Nat. Biotechnol., 20, 729–733. 
30. Gonzalez,V.M. (2008) Development of a novel ligand-receptor pair through protein 
engineering of the human estrogen receptor. 
31. Brocard,J., Warot,X., Wendling,O., Messaddeq,N., Vonesch,J.L., Chambon,P. and 
Metzger,D. (1997) Spatio-temporally controlled site-specific somatic mutagenesis in 
the mouse. Proc. Natl. Acad. Sci. U.S.A., 94, 14559–14563. 
32. Islam,K.M.D., Dilcher,M., Thurow,C., Vock,C., Krimmelbein,I.K., Tietze,L.F., 
Gonzalez,V., Zhao,H. and Gatz,C. (2009) Directed evolution of estrogen receptor 
proteins with altered ligand-binding specificities. Protein Eng. Des. Sel., 22, 45–52. 
33. Zhang,L., Spratt,S.K., Liu,Q., Johnstone,B., Qi,H., Raschke,E.E., Jamieson,A.C., 
Rebar,E.J., Wolffe,A.P. and Case,C.C. (2000) Synthetic zinc finger transcription 
factor action at an endogenous chromosomal site. Activation of the human 
erythropoietin gene. J. Biol. Chem., 275, 33850–33860. 
34. Porteus,M.H. and Carroll,D. (2005) Gene targeting using zinc finger nucleases. Nat. 
Biotechnol., 23, 967–973. 
35. Miller,J.C., Holmes,M.C., Wang,J., Guschin,D.Y., Lee,Y.-L., Rupniewski,I., 
Beausejour,C.M., Waite,A.J., Wang,N.S., Kim,K.A., et al. (2007) An improved zinc-
finger nuclease architecture for highly specific genome editing. Nat. Biotechnol., 25, 
778–785. 
36. Zhang,F., Cong,L., Lodato,S., Kosuri,S., Church,G.M. and Arlotta,P. (2011) Efficient 
construction of sequence-specific TAL effectors for modulating mammalian 
transcription. Nat. Biotechnol., 29, 149–153. 
37. Miller,J.C., Tan,S., Qiao,G., Barlow,K.A., Wang,J., Xia,D.F., Meng,X., Paschon,D.E., 
Leung,E., Hinkley,S.J., et al. (2011) A TALE nuclease architecture for efficient 
genome editing. Nat. Biotechnol., 29, 143–148. 
 
 32 
2.7	   Figures	  and	  tables	  
Figure 2.1 The structure of 17β-estradiol (E2), the natural ligand of estrogen receptor 
(ER), and the structure of 4,4-dihydroxybenzil (DHB). 
 
 
  Figure 1 – The Ligands 
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Figure 2.2 Diagrammatic representations of the constructs used in this study.  All 
constructs were cloned into pCMV5 for transient expression and pLNCX2 for stable 
integration.  P65 is the p65 activation domain of NF-κB.  VZ8 DBD is the VZ-8 zinc-
finger DNA binding domain that binds within VEGF-A promoter.  4S LBD is an 
engineered ER ligand binding domain that is activated by DHB.  (A) Construct used in 
p65 domain length optimization.  Hatched box represents variable p65 length.  (B) 
Variations of gene switch used in the initial screening to identify the best architecture.  
(C) Linker length optimization construct based on V24P. 
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Figure 2.3 Result from the initial architecture optimization screening.  V24P and 
P24V clearly outperformed the rest.  EGFP, EGFP+DHB, and GalP65 were used as 
negative controls.  EGFP+CoCl2 was used to emulate hypoxia and VZ8-P65 and F435P 
were used as positive controls.  Light bar – in the absence of DHB.  Dark bar – in 1 µM 
DHB. 
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Figure 2.4 Endogenous VEGF-A induction in transiently transfected HEK293.  (A) 
The horizontal axis labels represent the constructs’ names, and the V24P series contain 
GS linkers ranging from 0 to 110 amino acids long.  White bar is uninduced, and grey bar 
is induced with 1 µM DHB.  VZ8-P65 is a constitutive positive control and F435P is a 
positive control obtained from Bae et al. (26) to serve as a performance yardstick.  EGFP, 
Gal-P65, and Gal-P65 + DHB are negative controls.  Error bar represents standard error, 
and measurements have been obtained from two separate transfections, each assayed in 
duplicate.  The y-axis is truncated to allow clearer representation of the uninduced level.  
(B) Time response profile obtained by adding ligands to wells at 1-hour intervals for 12 
hours. 
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Figure 2.5 Ligand titration curve obtained using HEK293 cells stably integrated with 
V24P-GS60 gene switch.  Error bar represents standard error, and measurements have 
been obtained from two independent wells, each assayed in duplicate.  (A) Ligand 
titration curve of a heterogeneous integrant population. Black square series represents the 
measured, un-normalized, VEGF-A values.  The cell number at the time of sampling was 
used to normalize the grey circle series.  (B) Ligand titration curve of a highly inducible 
clonal integrant population, which was fitted to a Hill curve.  Min = 108, Max = 4588, 
Hill Coefficient = 2.3, Km = 38 nM, R2 = 0.9996.  (C) A representative series of ligand 
titration curves with shifted Km.  (D) A fit of the observed heterogeneous ligand titration 
curve using the series in (C) as a basis set, R2 = 0.9978. 
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Figure 2.6 Range of induction levels from 12 different stable integrant clones.  
Induction level ranged from 810 to 5100 pg/mL, averaged 2740 pg/mL.  Light bar – in 
the absence of DHB.  Dark bar – in 1 µM DHB. 
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Figure 2.7 Time courses obtained using HEK293 cells stably integrated with V24P-
GS60.  Error bars represent standard errors, and measurements have been obtained from 
two wells, each assayed in duplicate.  Values have been normalized by the cell number at 
the time of sampling.  Media (and ligand) was changed 24 hours prior the each sampling.  
(A) Heterogeneous time course 1, induced for 2 days at 1 µM DHB, rested for 6 days, 
repeat.  (B) Heterogeneous time course 2, induced for 4 days at 1µM DHB, rested for 4 
days, repeat.  (C) Heterogeneous time course 3, sustained induction at 1 µM DHB.  (D) 
Clonal population time course, sustained induction at 20 nM DHB with 200 nM spikes on 
day 1 and day 9. 
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Figure 2.8 Confocal microscopy.  Fluorescent gene switch constructs are created by 
inserting EGFP at the N-termini of the gene switch constructs used for transient 
expression.  The EGFP constructs are transfected into HEK293 cells grown on Ibidi poly-
D-lysine µ-slide (Ibidi, Verona, WI) using FuGene HD (Promega, Madison, WI).  Images 
are taken 24 hours later using Carl Zeiss LSM 700 confocal microscope (Thornwood, 
NY).  Nucleus stain channel shows the nuclei counter stained by Hoechst dye 
(Invitrogen, Carlsbad, CA).  EGFP channel shows the location of the EGFP-tagged gene 
switches.  
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Table 2.1 Comparison of assay conditions and induction values in previously 
reported VEGF-A induction studies.  When a particular condition or construct is shared 
between studies, the name and value is noted under Reference Values. *Not specified, 
assume typical working volume for the plate format. 
 
  
Author Liu et al. Pollock et al. Bae et al. Dent et al. This Work 
Cell Line HEK293 HEK293 HEK293 HEK293 HEK293 
Seed Density 1.60 x 105 3.00 x 105 1.00 x 105 Unknown 8.00 x 104 
Format 24-well 12-well 12-well Unknown 24-well 
Volume 500!L* 1mL* 1mL Unknown 500!L 
Accumulation Time 40h 48h 48h 24h 24h 
Peak VEGF value 700 5000 2200 1800 2500 
VEGF unit pg/mL pg/mg pg/mL pg/mL/24h pg/mL/24h 
Induction Type Constitutive Inducible Constitutive Inducible Inducible 
ELISA Kit R&D Systems R&D Systems Chemicon R&D Systems R&D Systems 
Reference values Hypoxia Hypoxia F435-P VZ+434-P65 F435-P 
400 3500 2200 2500 1100 
VZ+434-P65 
700 
Table 1 – Performance Comparison 
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Table 2.2 List of plasmids reported in this work 
 
Plasmid 
1 GAL-VP64 pCMV5 
2 GAL-p65 pCMV5 
3 p65(510-551)-VZ8-4S pCMV5 
4 p65(451-551)-VZ8-4S pCMV5 
5 p65(282-551)-VZ8-4S pCMV5 
6 p65(417-459)-VZ8-4S pCMV5 
7 p65(373-459)-VZ8-4S pCMV5 
8 p65(460-523)-VZ8-4S pCMV5 
9 V24P(451) pCMV5 
10 V24P-GS20 pCMV5 
11 V24P-GS40 pCMV5 
12 V24P-GS60 pCMV5 
13 V24P-GS80 pCMV5 
14 V24P-GS110 pCMV5 
15 P24V(451) pCMV5 
16 P24V-GS20 pCMV5 
17 P24V-GS40 pCMV5 
18 P24V-GS60 pCMV5 
19 V4 pCMV5 
20 Vg4 pCMV5 
21 4V pCMV5 
22 24V pCMV5 
23 V24 pCMV5 
24 4VP pCMV5 
25 P(451)V4 pCMV5 
26 P(284)V4 pCMV5 
27 VZ8-P65 pCMV5 
28 EGFP pCMV5 
29 V24P-GS60 pLNCX2 
30 V24P-EGFP pCMV5 
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Chapter	  3:	  Coordinated	   induction	   of	   multi-­‐gene	   pathways	   in	   S.	  
cerevisiae	  
3.1	   Introduction	  
Coordinated gene expression is an important tool in the biosynthesis of natural products, 
fine chemicals, and fuels (1-3). For example, the taxol biosynthetic pathway involves the 
synchronized action of at least 19 genes (4). In prokaryotes, genes involved in a 
biosynthetic pathway are often grouped together into an operon and are transcribed as a 
polycistronic mRNA under the regulation of a single promoter (5, 6). The operon 
structure makes it easy to regulate a large number of genes (7). In eukaryotes, especially 
filamentous fungi and even some plants, genes in the same pathway are also often 
grouped together into a gene cluster; but in contrast to that in prokaryotes, the genes are 
not under the same promoter, and may be subjected to independent regulation (8, 9). 
With rare exceptions, operons generally do not exist in eukaryotes (10).  
 
S. cerevisiae is an important industrial production host for heterologous pathways, and is 
generally suited for expressing pathways from fungi and plants, especially those 
involving cytochrome P450s (1). Being a eukaryote, it does not recognize operons, and 
each gene in a pathway will need to have its own promoters. This requirement can make 
construction of multi-gene pathways cumbersome. Traditionally, genes in pathways are 
usually broken up into multiple plasmids – at times only one gene on a plasmid (11), or 
two genes under a divergent promoter (12). In either format, the construction of a long 
pathway will require many plasmids and correspondingly many selection markers. 
Thanks to the recently developed large scale cloning methods, such as SLIC (13), Golden 
 43 
Gate (14), Gibson (15), and DNA Assembler (16), large concatenations of promoters and 
genes can now be routinely made. However, large pathways constructed thus far are 
driven by constitutive promoters, because with the exception of Golden Gate, most of the 
assembly methods are homology dependent (17, 18), and non-homologous inducible 
promoters that respond to the same inducer are limited. Furthermore, it is commonly 
believed that due to the active homologous recombination machinery in yeast, 
homologous promoters should be avoided even if they do not interfere with DNA 
assembly (1).  
 
GAL inducible promoters are commonly used for controlling gene expression in yeast 
(19). However, due to the high cost of the inducer, galactose, its use in industrial 
production is limited (20). To circumvent this problem, we have employed an estrogen 
receptor based gene switch to activate GAL promoters. Because of its nanomolar 
sensitivity, only 200 µmol 17β-estradiol is needed to fully induce a 20,000L reactor, at a 
cost of roughly $1.20 (Sigma Aldrich catalog 2012). 
 
In this chapter, we present a system of constructing and activating multi-gene pathways 
in S. cerevisiae. The system consists of three parts: (a) a collection of inducible 
promoters, (b) an estradiol inducible yeast strain, and (c) a method of DNA assembly that 
allows for easy construction of inducible pathways in one step from PCR products. As a 
proof of concept, we assembled a five-gene zeaxanthin pathway, demonstrated the 
estradiol-dependent production of zeaxanthin, and characterized the pathway’s behaviour. 
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3.2	   Results	  
3.2.1	   Inducible	  promoter	  collection	  
The availability of natural GAL responsive promoters is limited to the genes involved in 
galactose utilization. To address this limitation, we cloned the GAL1, GAL2, and GAL10 
promoters into a GFP reporter and induced the GFP expression using Gal-P65, a 
constitutive gene switch made from the fusion between the GAL4 DNA binding domain 
and the P65 activation domain. As shown in Figure 3.1A, the natural GAL promoters 
exhibited tight regulation – the uninduced fluorescence level was indistinguishable from 
the background fluorescence. 
 
To expand the dynamic range of the promoter collection, two sets of synthetic GAL 
responsive promoters were created. DNA fragments containing a varying number of 
consensus Upstream Activation Sequences (UAS) were joined to the TATA region of 
GAL1 and GAL2, creating the SYN1 and SYN2 collections of promoters respectively. 
As shown in Figure 3.1B and 3.1C, the induction strength of the promoter can be reduced 
by decreasing the number of UAS. In contrast to the tightly regulated GAL1 promoter, 
the SYN1 collection of promoters had noticeably higher basal levels. The SYN2 
collection of promoters did not suffer from increased basal level, and was generally 
weaker than the natural promoters. With the natural promoters and the SYN2 collection 
of promoters, induction strength across a wide dynamic range can be selected while the 
pathway of interest is maintained in tight control.  Further work on the engineering of 
GAL inducible promoters have recently been described by Blazeck et al. (25), which 
provided an even wider range of GAL inducible promoters to choose from. 
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3.2.2	   Gene	  switch	  engineering	  and	  strain	  development	  
Domain Selection and Permutation. To identify the optimum configuration for the gene 
switch, we tested different orders of functional domains and different activation domains. 
The gene switches were co-transformed with PGAL10-GFP and tested for their inducibility 
using 100 nM estradiol. As shown in Figure 3.2A, P65-Gal-ER (6GE) had the best 
compromise between induction level and basal expression level, and was selected for the 
development of a series of estradiol-inducible yeast strains.  
 
Estradiol-Inducible YZE Strains. After identifying the best gene switch configuration, we 
moved on to integrate the gene switch into YM954 so as to create a more convenient 
induction system as well as to reduce the number of plasmids required. The gene switch 
was integrated into the Lys2 locus without the use of antibiotic selection, thus leaving the 
most common auxotrophic markers intact and allowing the use of antibiotics for further 
genome engineering. Since the gene switch protein is not catalytically involved in the 
production of any desired compound, its over-expression will likely be detrimental to 
production. By placing the gene switch behind promoters of different strengths, the gene 
switch expression level will be varied in the different strains. Gene switch expression in 
YZE-19, YZE-55, YZE-100, and YZE-149 are driven by the ENO promoter and its 
derivatives – the numbering indicates their relative percentage strength to the wild type 
ENO promoter. The expression in YZE-PA is driven by the ADH1 promoter. The 
functionality of these strains was confirmed by observing fluorescence from the induction 
of PGAL10-GFP upon estradiol addition. The flow cytometry GFP channel histograms 
from the strains were shown in Figure 3.2B. The mean fluorescence value shifted towards 
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the right at higher promoter strengths. YZE-PA was not shown, but its histogram was 
indistinguishable from that of YZE-55.  
3.2.3	   Golden	  Gate	  pathway	  assembly	  
Pathway Assembly. Due to the limited availability of optimal inducible promoters, we 
designed the pathway assembly system based on the Golden Gate cloning method so that 
a single good inducible promoter can be re-used to control multiple genes if necessary. 
Details of Golden Gate cloning have been described by Carola et al. (14). Briefly, each 
fragment in the assembly is flanked by Type IIs restriction sites, e.g. BsaI, which cleaves 
the DNA away from its recognition sequence, leaving a user-defined 4 bp overhang. By 
judiciously choosing unique 4 bp overhangs, these fragments can be ligated together in a 
specific order to form the pathway. Because the restriction sites are lost when the correct 
ligation happens, the restriction and ligation reaction can be carried out simultaneously in 
one tube. 
 
To allow for modular assembly of pathways, we constructed a toolbox that contains 
plasmids carrying the intergenic terminator-promoters and a receiver plasmid that has the 
first promoter and the last terminator. The assembly scheme is shown in Figure 3.3A. For 
proof of concept, these plasmids were put together with the PCR products of the 
zeaxanthin pathway genes (Crt E, B, I, Y, and Z), and an inducible zeaxanthin pathway 
was constructed in a one-step Golden Gate reaction. For this pathway, TPGI1-PGAL2 was 
selected for all intergenic terminator-promoters, PGAL2 was selected as the first promoter 
and TADH1 was selected as the last terminator (Figure 3.3B and Figure 3.4). As all five 
genes are under the same promoter, it allows for easier characterization of the inducible 
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pathway. The assembly efficiency for the five-gene pathway was about 16% (2/12), and 
an alternative pathway that has TTPI1-PGAL10 in the T1-P2 position was also constructed at 
a similar efficiency. When the assembled pathway was co-transformed with a plasmid 
carrying the P65-Gal-ER gene switch, the inducible expression of zeaxanthin occurred 
only in the presence of estradiol (Figure 3.5).  
 
Plasmid Stability. The intergenic T-P regions are approximately 800 bp long, and since 
TPGI1-PGAL2 was used for all T-P positions, the resulting plasmid contained four 800 bp 
direct repeats. It is commonly believed that plasmids with repetitive sequences are 
unstable in S. cerevisiae due to the presence of a highly active homologous 
recombination machinery (1, 21). We therefore performed a test of plasmid stability to 
see if the pathway will remain intact over multiple generations of propagations. 
 
Since the complete zeaxanthin pathway produces a yellow compound (and thus yellow 
colonies) readily detectable by visual inspection, we assessed the plasmid stability by 
monitoring the number of white versus yellow colonies over continuous culture. The 
above zeaxanthin pathway was separately transformed into YZE-55 and YZE-PA, then 
plated onto selective plates. The initial colonies were collected, diluted, and re-plated 
with estradiol. The number of yellow and white colonies in this first re-plate was labelled 
as day 0 in Table 3.1. A yellow colony was then picked for uninduced continuous culture, 
diluting daily at 1/100, and an aliquot of the culture was plated with estradiol every two 
days (Figure 3.6). As shown in Table 3.1, there was no significant increase in the number 
of white colonies after 8 days of continuous culture. With the exception of the day 0 re-
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plate, there were hardly any white colonies. A cell growing from the day 0 re-plate to day 
8 saturated culture had gone through about 63 generations of divisions, more than enough 
to saturate a 20,000L batch reactor, and yet, only about 0.5% of the cells had lost the 
pathway. This showed that the zeaxanthin pathway, despite multiple direct repeat 
sequences, could be stably propagated in S. cerevisiae.  
3.2.4	   Inducible	  pathway	  characterization	  
Protein Level Induction. While the promoters were characterized individually before the 
pathway assembly, putting multiple promoters together in the same plasmid may result in 
position dependency. Therefore, we sought to investigate whether the protein induction 
levels depend on where the gene is situated within the long concatenation of gene 
cassettes. Using the same toolbox plasmids as above, five more pathways were 
assembled, each with a different zeaxanthin pathway gene replaced with the GFP gene. 
The GFP gene in the five plasmids are thus all under PGAL2 promoters. Assuming that 
neighbouring structural genes do not interfere with promoter activity, any difference in 
induction level can be attributed to positional effect. As shown in Figure 3.7A, GFP at all 
five positions were estradiol inducible. The basal level expressions were 
indistinguishable from background fluorescence. The protein induction level appeared to 
dip at the 3rd and 4th position, but the expression level at all five positions varied by no 
more than two-fold. This showed that the genes at all five positions can be effectively 
regulated, even though the exact induction strength has some position dependency. 
 
mRNA Level Induction. Next, we investigated whether all five pathway genes can be 
induced simultaneously. Because the proteins were not tagged, we instead measured the 
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mRNA level induction of the zeaxanthin pathway genes. As shown in Figure 3.7B, all 
five zeaxanthin pathway genes can be induced, and the trend in relative induction 
strength is the same as what we have observed from the GFP fluorescence measurement. 
This gave further evidence of the positional dependency of promoter strength. As mRNA 
and protein abundance are not linearly correlated, a big change in mRNA level doesn’t 
correspond to a big change in protein expression level, only the trend is consistent. 
Interestingly, when mRNA induction ratio and protein abundance as reported by GFP 
fluorescence are plotted against each other, a power-law trend emerged (Figure 3.8) – 
which coincides with the trend observed by Beyer et al. in their genome scale study of 
transcription-translation relationships in S. cerevisiae (22).  
 
Inducible Strain Comparison. Production of zeaxanthin was compared in the five YZE 
strains that differed in their promoters driving the gene switch expression. The inducible 
zeaxanthin pathway was transformed into the five strains and tested for their zeaxanthin 
production at 24 and 48 hours after induction. After sampling at 24h, the culture was re-
inoculated 1/100 into fresh media. As shown in Figure 3.5B, high gene switch promoter 
strengths, e.g. YZE-100 and YZE-149, are bad for production. YZE-19, 55, and YZE-PA 
showed similar production level at 24h but YZE-PA’s production decreased after re-
inoculation. YZE-19 and YZE-PA were picked for further comparison. 
 
Production Time Curve. YZE-19 and YZE-PA, each harbouring an inducible pathway 
plasmid, were compared to YM954 harbouring a constitutive pathway. The constitutive 
pathway was obtained from a previous publication and used as a benchmark in our 
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comparison (16). To make the result more comparable, the constitutive pathway was re-
cloned into pRS416K2 which is the backbone of the inducible pathway, and YZE’s 
parent strain, YM954, was used to host the pathway. As shown in Figure 3.7C, YZE-19 is 
the best producer. At 72h post induction, YZE-19 accumulated roughly twice the 
zeaxanthin compared to YZE-PA and about 50-fold more compared to the constitutive 
pathway. The measured concentration by HPLC was 1.5 µg/mL, which corresponds to 15 
ng/OD600 cells or about 75 µg/g dry cell weight. 
 
Ligand Titration. To identify an optimal inducer concentration, we performed a ligand 
titration in YZE-19 and YZE-PA. The strains harbouring the inducible pathway were 
subjected to different estradiol concentration, and the zeaxanthin production was 
measured after 48h. In agreement with the time course experiment, YZE-19 is a better 
producer. As shown in Figure 3.7D, it is in fact more sensitive to estradiol than YZE-PA. 
Peak induction in YZE-19 can be obtained at 10-8 M estradiol.  
3.3	   Discussion	  
In this study, we have presented a system for the construction and regulation of multi-
gene pathways in S. cerevisiae. Genes of an entire pathway can be concatenated together, 
each driven by an inducible promoter, forming a transcriptional unit that can be regulated 
as a whole – similar to what can be achieved by a bacterial operon. By using inducible 
promoters of different strengths for different genes, it is possible to balance the flux 
through the pathway, which is the main challenge in metabolic engineering and synthetic 
biology (23). 
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We currently have a set of six promoters that are tightly regulated, with induction 
strength that spans an 8-fold difference from the weakest to the strongest. More inducible 
promoters have recently been developed by Blazeck et al. (24), and can easily be 
incorporated into our pathway construction system. As indicated in Figure 3.7D, 
induction strength can depend on the gene switch’s expression level, and can therefore 
differ in the different YZE strains. When using promoter strength to tune pathway gene 
expressions, it is also possible to pick induction strength through varying the ligand 
concentration. However, ligand titration curves need to be obtained in the host strain to 
find out what the induction level is at any given ligand concentration. Furthermore, in this 
non-saturation range, small differences in ligand concentration can cause large 
differences in induction strength, making it difficult to control the induction level. For the 
above reasons, we find that it is best to vary induction strength by varying maximum 
induction levels. 
 
Based on the results of gene switch configuration assessment, we integrated the best gene 
switch into the chromosome to create five inducible yeast strains differing in gene switch 
expression levels. When used in conjunction with the inducible pathways, no additional 
plasmid is necessary. As shown in Figure 3.5B, high gene switch expression can be 
detrimental to the production of the desired product. Due to high clonal variation in 
adaptation, when a pathway is transformed into any given strain and induced on a plate, 
colonies with different degrees of yellow colouration (indicating zeaxanthin production) 
will occur. We picked both light- and dark-yellow colonies, assayed their product, and 
confirmed that they were all producing zeaxanthin, just at different levels (data not 
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shown). High producing colonies occur at a frequency of roughly 1 in 10, and the 
adaptation can be propagated. When comparing the zeaxanthin production level in the 
different strains, we selected the darkest yellow colonies from each plate. 
 
Using the Golden Gate assembly method and our plasmid toolbox, the 5-gene zeaxanthin 
pathway can be assembled from their PCR products in a single step. This corresponds to 
a simultaneous ligation of 10 fragments forming a 13.3 kb plasmid with an efficiency of 
16%. Similar efficiency was observed for the assembly of 2 zeaxanthin pathways and 5 
GFP-replaced pathways. As the correct pathways could be picked from a reasonable 
number of colonies, no optimization was performed. For longer pathways, optimization 
of the Golden Gate reaction condition will probably be necessary, and should 
optimization fail, a two-stage hierarchical assembly can instead be used. In that case, the 
toolbox will be expanded to include two to three ampicillin-resistant intermediate 
plasmids. PCR products of the genes and the T-P fragments from T-P plasmids will first 
be assembled into the intermediate plasmids, up to 5 genes at a time. The intermediate 
plasmids will then be used as the substrate for a second Golden Gate reaction, which puts 
the intermediate assemblies together into the final receiver plasmid. If a target gene 
contains the BsaI restriction site, it is possible to PCR-amplify the gene in multiple 
segments, breaking and replacing each natural BsaI site through primers. These 
fragments can then be used in the 1-step Golden Gate assembly system as per normal. 
Another way to work around the restriction site is to use another Type IIs restriction 
enzyme that gives a 4 bp 5’ overhang for the problematic target gene, and break the 1-
step assembly to 2-step assembly involving first digesting and then ligating. 
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The initial transformations of the assembled zeaxanthin pathway have a significant 
fraction of white colonies (Table 3.1), but when a yellow colony is picked and 
propagated, only 0.5% white colony can be observed after 8 days of continuous 
cultivation, with no increase in the percentage of white colonies over the 8 days. This 
suggests that the plasmid may be less stable in E. coli such that the initial plasmid 
preparation contained a small portion of truncated recombined plasmids, and the 
proportion was magnified through the preferential transformation of smaller plasmids. 
Interestingly, when the plasmid for yeast transformation was prepared in the Stbl3 strain 
instead of the TOP10 or DH5α strains, the fraction of white colonies decreased 
drastically. Since Stbl3 is a strain better suited for amplifying unstable plasmids, it gives 
further evidence for plasmid instability in E. coli. 
 
Ideally, promoter strength should be independent of its position in the pathway, but this 
was not the case, at least for the GAL2 promoter. We observed that the induction strength 
tended to dip towards to middle of the pathway, and this has been supported at both 
protein (Figure 3.7A) and mRNA (Figure 3.7B) levels. One possible cause of this 
observation could be the 1-D search mechanism of DNA binding proteins. DNA binding 
proteins look for their cognate sequences in many ways, and one of the major search 
mechanisms is by first binding non-specifically to DNA, then performing a 1-D search 
along the DNA (25-27). The promoters at the flanks have access to a large ring of non-
cognate DNA, i.e. the plasmid backbone, and the gene switch will therefore have a higher 
chance of finding these promoters. In contrast, the promoters in the middle will have a 
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much smaller binding area, and will have to rely more on a 3-D diffusion mechanism. 
More experiments are needed to verify this explanation and come up with a way to 
predict the modification of induction strength due to positional effect. 
 
Despite some positional dependency of induction strength, the pathway is tightly 
regulated – with no measurable production in the absence of estradiol. To benchmark the 
induced production, we used a constitutive zeaxanthin pathway previously reported in 
literature (16). Under the condition of our production time curve experiment, the 
inducible pathway resulted in about 50-fold higher production level than the constitutive 
pathway. In making the comparison, we note that the genes on the constitutive pathway 
have five different constitutive promoters. Since constitutive promoters can sometimes be 
repressed under certain culture conditions, we may have just picked a poor production 
condition for the constitutive pathway. While we have not demonstrated the superior 
production capacity of an inducible pathway due to the above reason, we have at least 
demonstrated the greater reliability and predictability of an inducible system. Indeed, in 
another previous previously reported zeaxanthin production using S. cerevisiae, the 
authors achieved a similar production level as our inducible pathway using a mixture of 
inducible and constitutive promoters (2, 28). 
 
We chose GAL4 DBD and its corresponding UAS in our study because the GAL4 DBD 
based induction system has been well characterized and it is commonly employed for 
inducible expression in yeast. There is, however, a drawback in the system – being a 
native yeast protein, there are multiple regulatory and interaction targets for GAL4 DBD 
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and some of these interactions can lead to unexpected phenotypes. For example, the YZE 
strains will not flocculate when induced, but if un-induced, will flocculate when the 
carbon source is exhausted. This could be due to interactions of GAL4 with other cellular 
signalling pathways, with the overall effect of tricking the cell into acting as if there is 
still galactose around.  
 
3.4	   Conclusions	  and	  outlook	  
With the tools introduced in this chapter, biosynthetic pathways can be easily refactored 
and studied in S. cerevisiae. More importantly, entire pathways can now be predictably 
and reliably induced using estradiol, a commonly available chemical. If desired, the ER 
LBD can also be engineered to generate new orthogonal ligand-receptor pairs, giving us 
the ability to regulate multiple pathways simultaneously and orthogonally (29-31). The 
ability to coordinate the expression of multiple genes in S. cerevisiae will be a useful 
addition to the toolbox of microbiologists, metabolic engineers, and synthetic biologists. 
3.5	   Material	  and	  methods	  
3.5.1	   Strains,	  plasmids,	  media,	  reagents,	  and	  cell	  cultivation	  
TOP10 (F- mcrA Δ(mrr-hsdRMS-mcrBC) φ80lacZΔM15 ΔlacΧ74 recA1 araD139 Δ(ara- 
leu) 7697 galU galK rpsL (StrR) endA1 nupG λ-) and Stbl3 (F- mcrB mrr hsdS20 (rB-, mB-
) recA13 supE44 ara-14 galK2 lacY1 proA2 rpsL20 (Str) xyl-5 λ- leu mtl-1r ) (Life 
Technologies, Carlsbad, CA) were used for routine plasmid cloning and amplification in 
E. coli. YM954 (MATa; ura3-52 his3-200 ade2-100 lys2-801 trp1-901 leu2-3,112 gal4-
542 gal80-538) (kindly provided by Florence Vignols and Stanley Fields) was used for 
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yeast experiments. Yeast strains were cultivated in either synthetic dropout medium 
(0.17% Difco yeast nitrogen base without amino acids and ammonium sulfate, 0.5% 
ammonium sulfate, and 0.083% amino acid dropout mix) or YPA medium (1% yeast 
extract, 2% peptone, and 0.01% adenine hemisulfate) supplemented with 2% glucose as a 
carbon source. E. coli strains were cultured in Luria broth (LB; Fisher Scientific, 
Pittsburgh, PA, USA). 
 
YZE-19 through 149 and YZE-PA were created in this study by integrating the P65-Gal-
ER (6GE) gene switch into YM954 at the LYS2 locus, and are lys2+. pLys2-
PENO19,55,100,149-6GE and pLys2-PADH1-6GE were linearized with DraIII and transformed 
into YM954 by chemical transformation as described elsewhere (32). Integrants were 
selected using SC-Lys plates and confirmed by PCR as well as functional assay.  
 
All restriction and DNA processing enzymes were obtained from New England Biolabs 
(Ipswich, MA) and all chemicals were obtained from Sigma Aldrich (St Louis, MO) 
unless otherwise specified. PCR reactions were carried out using Phusion DNA 
Polymerase (Dharmacon, Lafayette, CO) and primers from Integrated DNA Technologies 
(Coralville, IA). 
3.5.2	   Plasmid	  construction	  
The natural GAL promoters were PCR amplified directly from the genomic DNA of S. 
cerevisiae. The resulting PCR products were overlap extended with another PCR 
fragment encoding the green fluorescent protein (GFP) and the ADH1 terminator. The 
promoter-gene-terminator cassette was subsequently ligated into pRS416 centromeric 
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vector (ATCC 87521) via BamHI and SacI to create pRS416-Gal1-GFP, pRS416-Gal2-
GFP, and pRS416-Gal10-GFP. The synthetic GAL UASes were synthesized from 
overlap extension of oligonucleotides. These were overlap extended with the TATA box 
region of Gal1 and Gal2 to create the SYN1 and SYN2 series of promoters respectively, 
and subsequently cloned into pRS416 to create pRS416-SYN1-GFP and pRS416-SYN2-
GFP. Sequences of SYN1 and SYN2 promoter can be found in Table 3.4. 
 
The gene switch constructs were generated by ligation of either a P65 or GAL4 activation 
domain (AD) with an estrogen receptor ligand binding domain (ER LBD) and a GAL4 
DNA binding domain (DBD). The P65 and ER LBD were PCR amplified from human 
genomic DNA whereas the GAL4 AD and DBD were amplified from S. cerevisiae 
genomic DNA. The fragments were cloned directly into pRS414-PMT, which is a 
pRS414 vector (ATCC 87519) modified to contain an ADH1 promoter and ADH1 
terminator interspaced by a multiple cloning site.  
 
The gene switch integration plasmids, pLys2-PENO19,55,100,149-6GE and pLys2-PADH1-6GE 
were created by ligating the promoter fragments (EcoRI, KpnI) and 6GE-TADH1 (KpnI, 
MluI) into pLys2 (EcoRI, MluI), which is pNEB193 (New England Biolabs, Ipswich, 
MA) with the LYS2 gene inserted into the AatII site. PENO19, 55, 100, 149 promoters were 
obtained by random mutagenesis of the wild type ENO promoter as described elsewhere 
(33).  
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The T-P plasmids were constructed by the ligation of the PGI1 terminator (AflII, EcoRI) 
and the GAL2 promoter (EcoRI, XbaI) into pFUS_A (AflII, XbaI) with appropriate BsaI 
sites introduced at the two ends of the T-P cassette. pFUS_A is an E. coli plasmid with a 
spectinomycin resistance marker as described elsewhere (34). The PGI1 terminator was 
PCR amplified from pRS416-Zeax which is a constitutive zeaxanthin pathway as 
described elsewhere (16), whereas the GAL2 promoter was PCR amplified from the 
above-described pRS416-Gal2-GFP. 
 
The Golden Gate receiver plasmid, containing the first promoter and the last terminator 
interspaced by a BsaI-flanked LacZα cassette, was constructed by the overlap extension 
of the GAL2 promoter (from pRS416-Gal2-GFP), LacZα cassette (from pFUS_A), and 
ADH1 terminator (from pRS416-Gal2-GFP). The overlap extended fragment was cloned 
into pRS416K2 via HindIII and NotI. pRS416K2 was modified from pRS416 by the 
removal of all BsaI sites, the LacZα remnant, the f1 origin, and by the replacement of 
AmpR with KanR.  
3.5.3	   Pathway	  assembly	  
The Golden Gate reaction for pathway assembly was carried out in 20 µL using 100 ng of 
receiver plasmid, 100 ng of each T-P plasmid, 10 ng/kb of the PCR gene fragments, 1 µL 
of BsaI-HF, and 1 µL High Concentration T4 DNA ligase, in 1X T4 ligase buffer. The 
reaction was thermocycled as follows: 37 ºC for 10 min, (37 ºC for 5 min, 16 ºC for 10 
min) repeated 10 times, 37 ºC for 10 min, 75 ºC for 5 min. The ligation product was 
transformed into TOP10 competent cells (Life Technologies, Carlsbad, CA) by heat-
shock, and white colonies on X-GAL/IPTG plates were screened for the correctly 
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assembled pathway. Primer sequences used to obtain the PCR gene fragments are listed 
in Table 3.2. 
3.5.4	   Measurement	  of	  GFP	  expression	  
GFP expression level was measured by flow cytometry using LSRII (BD Biosciences, 
Franklin Lakes, NJ). Single colonies were picked into liquid synthetic dropout media and 
grown overnight with or without induction. Small aliquots of the cultures were then 
washed and resuspended in phosphate buffered saline for flow cytometry analysis. 
3.5.5	   Measurement	  of	  zeaxanthin	  production	  
Cells from 6 mL of S. cerevisiae dropout media culture were collected by centrifugation, 
resuspended in 1 M sorbitol, 10 mM Tris Buffer pH 7.4, 5 U/mL Zymolyase (Zymo 
Research, Irvine, CA), and incubated at 37 ºC for 45 min. Cells were then collected again 
by centrifugation and 600 µL methanol was used to extract the zeaxanthin directly. For 
quantification, 80 µL of methanol extract was loaded onto an Agilent ZORBAX SB-C18 
column and monitored at 450 nm on an Agilent 1100 series HPLC (Agilent 
Technologies, Palo Alto, CA). The pump program was 0.6 mL/min, 100% methanol for 
10 min. Elution was monitored at 450 nm with reference set at 360 nm. Authentic 
zeaxanthin from Sigma (St Louis, MO) was used as a standard. 
3.5.6	   RNA	  preparation	  and	  quantitative	  PCR	  
Yeast colonies were picked from synthetic dropout plates into 3 mL synthetic dropout 
medium and grown overnight at 30 °C with shaking at 250 RPM to saturation. 100 µL of 
overnight culture was then used to inoculate 3 mL of fresh media, and estradiol was 
added to the appropriate samples. After growing for 18 hours, cells from 0.5 mL of each 
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culture were harvested by centrifugation. RNA was then isolated using the RNeasy Mini 
Kit (QIAGEN, Valencia, CA) according to the manufacturer’s protocol.  1 µg of the 
resulting total RNA was treated by 10 units of recombinant DNaseI (Takara Bio, Otsu, 
Shiga, Japan) in 20 µL for 40 minutes according to the manufacturer’s protocol. 
Complementary DNA (cDNA) was then synthesized using the iScript cDNA Synthesis 
Kit (Bio-Rad, Hercules, CA) according to the manufacturer’s protocol and stored at -20 
°C until use. Quantitative PCR primers were designed using the Primer3Plus software 
(http://www.bioinformatics.nl/cgi-bin/primer3plus/primer3plus.cgi) (Table 3.3).  
Reactions were performed using Applied Biosystems 7900HT Fast Real-Time PCR 
System (Applied Biosystems, Austin, TX) according to the manufacturer’s protocol. 
Expression was quantified relative to the ALG9 gene using the standard curve method 
(35). 
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3.7	   Figures	  and	  tables	  
Figure 3.1 The behaviour of GAL inducible promoters, monitored via GFP 
expression and induced using Gal-P65. The GFP channel histograms obtained from flow 
cytometry are shown. Black indicates uninduced sample and red indicates induced 
sample. The sample identity and the percentage of positives are shown within each 
histogram. (A) The behaviour of natural GAL inducible promoters cloned from S. 
cerevisiae. (B) The behaviour of synthetic GAL inducible promoters, which were 
generated by fusing the synthetic UAS sequences with the TATA box of the GAL1 
promoter. (C) Similar to (B), but fused with the TATA box of the GAL2 promoter. 
 
 
Figure 3.2 (A) Gene switch activity monitored via GFP expression, and measured 
using flow cytometry. GFP expression levels are represented by the arithmetic means of 
GFP fluorescence (arbitrary unit). The mean of negative control has been subtracted from 
that of the samples. Blue columns represent uninduced samples, and red columns 
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represent induced samples. Values are the average of two independent samples and error 
bar indicates the standard error. Labels: CTR is negative control with empty plasmids, 
and Y2H is a yeast two hybrid system positive control from (29). GE, EG, AGE, AEG, 
6GE, and 6EG are different combinations and permutations of Gal4 DBD(G), ER 
LBD(E), P65(6), and Gal4 AD(A) ordered from the N-terminus of the resulting gene 
switch protein. (B) Inducibility of the YZE strains monitored via GFP expression. The 
GFP channel histograms are shown. Black indicates negative control without gene 
switch, blue indicates uninduced sample, and red indicates induced sample. 
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Figure 3.3 (A) The inducible pathway assembly scheme. The T-P plasmids have 
BsaI-excisable terminator and promoter fragments, and the receiver plasmid has BsaI-
excisable LacZα marker for blue-white screening. The toolbox plasmids together with the 
PCR products of the pathway genes can be used to assemble an inducible pathway in a 
Golden Gate one pot reaction. BsaI sites are in light blue, Kan is the kanamycin 
resistance gene, Spe is the spectinomycin resistance gene. (B) A schematic of the 
assembled inducible zeaxanthin pathway. All 4 intergenic T-P fragments are identical 
except for the 4bp overhang region. 
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Figure 3.4 Unique 4 bp overhang assignment in pathway assembly. By judiciously 
choosing the 4 bp overhang created by BsaI, pathways can be assembled in a user-
specified order. The TP fragments and the receiver fragment (pRS416K2) are supplied by 
toolbox plasmids, whereas the Crt fragments are PCR products. 
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Figure 3.5 (A) HPLC trace showing the inducible production of zeaxanthin. (B) 
Zeaxanthin production in different YZE hosts. Blue columns represent data from the first 
24-hour samples. At the end of the 24-hour period, cells were re-inoculated into fresh 
media for another 24-hour. Red columns represent data from the second 24-hour samples. 
The values represent the average of 4 independent samples, and the error bar represents 
the standard error. 
 
 
 
 
  
0
0.02
0.04
0.06
0.08
0.1
0.12
0.14
19 55 100 149 PA
Ze
ax
an
th
in
(µ
g/
m
L)
A B
-20
0
20
40
60
80
0 2 4 6 8
A
bs
45
0
(m
A
U
)
Time (min)
Uninduced
Induced
Zeaxanthin	  Standard
 69 
Figure 3.6 Inducible zeaxanthin pathway stability assessment. The plasmids 
harboring the assembled zeaxanthin pathway were purified form E. coli and used to 
transform YZE-PA and YZE-55.  After two days incubation, the initial colonies were 
collected and re-plated onto an SC-URA plate with 0.1 µM estradiol. When colonies 
reappeared, the numbers of white and yellow colonies were counted. A yellow colony 
was subsequently picked for continuous cultivation in SC-URA media, diluted daily at 
1/100. Aliquots of the continuous culture were plated on SC-URA with estradiol on day 
2, 4, 6, and 8. 
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Figure 3.7 (A) Protein level induction at the different positions using EGFP as the 
reporter. The genes along the pathway are arranged from 5’ to 3’ in the order Crt E-B-I-
Y-Z. Zea is the negative control with the 5-gene inducible zeaxanthin pathway without 
any EGFP gene in it. E, B, I, Y, Z:EGFP have their respective zeaxanthin pathway gene 
replaced by EGFP. The uninduced EGFP-replaced pathways have identical basal 
expression levels, and they have been collapsed under crt:EGFP. The values represent the 
average of 4 independent samples, and the error bar represents the standard error. (B) 
mRNA level induction at the different positions as measured by quantitative RT-PCR. 
The value represents the average of 2 independent samples, and the error bar represents 
the standard error. (C) Production time course that benchmarks the inducible pathway in 
two different YZE strains to a constitutive pathway in YM954. The values represent the 
average of 3 independent samples, and the error bar represents standard error. (D) Ligand 
titration curve of the zeaxanthin production against the estradiol concentration. The 
values represent the average of 2 independent samples, and the error bar represents 
standard error. 
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Figure 3.8 mRNA induction vs EGFP expression. 
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Table 3.1 Assessment of plasmid stability. White colony is an indication that the 
yeast cell has lost at least part of the zeaxanthin pathway. The colony counts are the 
average of two independent experiments.  
 
Integrant Time Total Colony White Colony % White 
 
Day 0 60 12 20.00 
 
Day 2 243.5 0.5 0.21 
YZE-55 Day 4 195 1 0.51 
 
Day 6 360 1 0.28 
 
Day 8 267.5 1.5 0.56 
     
 
Day 0 110 39 35.45 
 
Day 2 295 1.5 0.51 
YZE-PA Day 4 195.5 0.5 0.26 
 
Day 6 404 2 0.50 
  Day 8 267 1 0.37 
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Table 3.2 Primer sequences used in zeaxanthin pathway cloning. The black portion 
is gene-specific, and the blue portion is position-specific. The 4 bp overhangs are 
underlined, and they determine the order in which the genes are assembled. 
 
Primer Name Primer Sequences (5'-3') 
BsaI>-CrtE For CTTGAAGGTCTCCCATA ATGACGGTCTGCGCAAAAAAACAC 
CrtE-<BsaI Rev CAATAAGGTCTCGCTAC TTAACTGACGGCAGCGAGTTTTTTGTC 
BsaI>-CrtB For CTTGAAGGTCTCCCAAA ATGAATAATCCGTCGTTACTCAATCATGCG 
CrtB-<BsaI Rev CAATAAGGTCTCGGATG CTAGAGCGGGCGCTGCCAG 
BsaI>-CrtI For CTTGAAGGTCTCCAACA ATGAAACCAACTACGGTAATTGGTGCAGG 
CrtI-<BsaI Rev CAATAAGGTCTCGGTCA TCATATCAGATCCTCCAGCATCAAACCTG 
BsaI>-CrtY For CTTGAAGGTCTCCCACA ATGCAACCGCATTATGATCTGATTCTCG 
CrtY-<BsaI Rev CAATAAGGTCTCGCGGA TTAACGATGAGTCGTCATAATGGCTTGC 
BsaI>-CrtZ For CTTGAAGGTCTCCTACA ATGTTGTGGATTTGGAATGCCCTG 
CrtZ-<BsaI Rev CAATAAGGTCTCGGGAT TTACTTCCCGGATGCGGGC 
 
Table 3.3 Primer sequences used in quantitative RT-PCR. 
 
Primer Name Primer Sequence (5’-3’) 
ALG9 Forward CTACCATCAGAACCGCATTC 
ALG9 Reverse TCCATGATACAGGAGCAAGC 
crtB Forward TTGCGGCTTTTCAGGAAG 
crtB Reverse AATAGCGCAGCGTATCATCC 
crtE Forward AACTGCTGGACGATTTGACC 
crtE Reverse TCACTGGCAAGCTGAAGATG 
crtI Forward AAGCCGTGCATTTAGAGGAC 
crtI Reverse TCTGCAGTTTGTTGGACTGC 
crtY Forward TTGACTGAGAGCCAACATCG 
crtY Reverse TGTCGCTGTAAAACCTCAGC 
crtZ Forward GCCATTCCGCTATATTCCAC 
crtZ Reverse CGCATAGAGGAAGCCAAAAG 
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Table 3.4 SYN1 and SYN2 promoter sequences. 
 
SYN1A (4 x UAS) 
TATTGAAGTACGGAGTGTTAGGCTCCGAAGTCCGGAGTGTTAGGCTCCGGTACACGGAG
TGTTAGGCTCCGGTACACGGAGTGTTAGGCTCCG-TATA GAL1 
 
SYN1B (3 x UAS) 
TATTGAAGTACGGAGTGTTAGGCTCCGTCAGACGTCACGGAGTGTTAGGCTCCGGTACA
CGGAGTGTTAGGCTCCG-TATA GAL1 
 
SYN1C (2 x UAS) 
TATTGAAGTACGGAGTGTTAGGCTCCGGTACACGGAGTGTTAGGCTCCG-TATA GAL1 
 
SYN2A (4 x UAS) 
TTGGAAAGCTCGGAAGCCTCTCCTCCGATACACGGAAGACTCTCCTCCGGATAGCCTCG
GAAGACTCTCCTCCGGGTCCCGGAAGACTCTCCTCCG-TATA GAL2 
 
SYN2B (3 x UAS) 
TTGGAAAGCTCGGAAGACTCTCCTCCGGATAGCCTTACGGAAGACTCTCCTCCGGGTAC
CGGAAGACTCTCCTCCG-TATA GAL2 
 
SYN2C (2 x UAS) 
TTGGAAAGCTCGGAAGACTCTCCTCCGATACACGGAAGACTCTCCTCCG-TATA GAL2 
 
TATA GAL1 
AAAGATTCTACAATACTAGCTTTTATGGTTATGAAGAGGAAAAATTGGCAGTAACCTGG
CCCCACAAACCTTCAAATTAACGAATCAAATTAACAACCATAGGATGATAATGCGATTA
GTTTTTTAGCCTAATTAATCAGCGAAGCGATGATTTTTGATCTATTAACAGATATATAA
ATGGAAAAGCTGCATAACCACTTTAACTAATACTTTCAACATTTTCAGTTTGTATTACT
TCTTATTCAAATGTCATAAAAGTATCAACAAAAAATTGTTAATATACCTCTATACTTTA
ACGTCAAGGAGAAAAAACTATAATG 
 
TATA GAL2 
CGAGATTAGTTAAGCCCTTCCCATCTCAAGATGGGGAGCAAATGGCATTATACTCCTGC
TAGAAAGTTAACTGTGCACATATTCTTAAATTATACAACATTCTGGAGAGCTATTGTTC
AAAAAACAAACATTTCGCAGGCTAAAATGTGGAGATAGGATAAGTTTTGTAGACATATA
TAAACAATCAGTAATTGGATTGAAAATTTGGTGTTGTGAATTGCTCTTCATTATGCACC
TTATTCAATTATCATCAAGAATAGTAATAGTTAAGTAAACACAAGATTAACATAATAAA
AAAAATAATTCTTTCATAATG 
 
 
 
 
